​

Twist Bioscience (TWST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TWST Stock Forecast

Twist Bioscience (TWST) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $67.83, with a high of $85.00 and a low of $52.00. This represents a -8.40% decline from the last price of $74.05.

$30 $41 $52 $63 $74 $85 High: $85 Avg: $67.83 Low: $52 Last Closed Price: $74.05

TWST Stock Rating

Twist Bioscience stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (84.62%), 1 Hold (7.69%), 1 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 1 11 0 Strong Sell Sell Hold Buy Strong Buy

TWST Price Target Upside V Benchmarks

TypeNameUpside
StockTwist Bioscience-8.40%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks19.09%

Price Target Trends

1M3M12M
# Anlaysts2614
Avg Price Target$82.50$68.33$55.00
Last Closing Price$74.05$74.05$74.05
Upside/Downside11.41%-7.72%-25.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26181--10
May, 26172--10
Apr, 26172--10
Mar, 26172--10
Feb, 26172--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 11, 2026David WestenbergPiper Sandler$85.00$67.7725.42%14.79%
May 22, 2026Puneet SoudaLeerink Partners$80.00$58.8435.96%8.04%
May 05, 2026Subbu NambiGuggenheim$60.00$56.196.78%-18.97%
May 05, 2026Catherine Ramsey SchulteRobert W. Baird$65.00$56.1915.68%-12.22%
May 04, 2026Barclays$65.00$56.1915.68%-12.22%
Apr 14, 2026Luke SergottBarclays$55.00$50.389.17%-25.73%
Feb 03, 2026Robert W. Baird$50.00$47.734.76%-32.48%
Feb 03, 2026Evercore ISI$52.00$47.429.66%-29.78%
Feb 03, 2026Barclays$50.00$46.816.81%-32.48%
Jan 05, 2026Evercore ISI$42.00$34.3522.27%-43.28%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 11, 2026Piper SandlerOverweightinitialise
May 05, 2026GuggenheimBuyBuyhold
May 04, 2026BarclaysOverweightOverweighthold
Apr 14, 2026BarclaysOverweightOverweighthold
Feb 03, 2026Evercore ISIOutperformOutperformhold
Feb 03, 2026BarclaysOverweightOverweighthold
Jan 26, 2026GuggenheimBuyBuyhold
Jan 08, 2026Cowen & Co.BuyBuyhold
Jan 05, 2026Evercore ISIOutperformOutperformhold
Dec 15, 2025BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-3.15$-4.04$-3.60$-3.60$-1.30----
Avg Forecast$-3.14$-4.47$-3.72$-3.72$-2.25$-1.66$-1.08$-0.49$0.04
High Forecast$-2.98$-3.57$-3.66$-3.70$-2.09$-1.50$-0.64$-0.48$0.04
Low Forecast$-3.31$-5.36$-3.76$-3.73$-2.35$-1.84$-1.85$-0.49$0.04
Surprise %0.32%-9.62%-3.23%-3.23%-42.22%----

Revenue Forecast

$100M $230M $360M $490M $620M $750M Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$132.33M$203.56M$245.11M$312.97M$376.57M----
Avg Forecast$130.95M$179.37M$241.58M$310.91M$373.27M$438.47M$522.91M$605.50M$708.05M
High Forecast$136.44M$215.25M$242.01M$311.41M$375.62M$440.20M$524.65M$610.70M$714.14M
Low Forecast$125.78M$143.50M$240.00M$310.12M$372.11M$434.79M$521.17M$597.70M$698.93M
Surprise %1.06%13.49%1.46%0.66%0.88%----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-152.10M$-217.86M$-204.62M$-208.73M$-77.67M----
Avg Forecast$-164.95M$-214.13M$-205.80M$-215.37M$-128.91M$-96.84M$-80.93M$-28.14M$2.32M
High Forecast$-131.96M$-171.31M$-164.64M$-214.51M$-121.43M$-86.98M$-37.20M$-27.67M$2.35M
Low Forecast$-197.93M$-256.96M$-246.96M$-216.24M$-136.39M$-106.70M$-107.50M$-28.45M$2.28M
Surprise %-7.79%1.74%-0.58%-3.09%-39.75%----

TWST Forecast FAQ

Is Twist Bioscience stock a buy?

Twist Bioscience stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Twist Bioscience is a favorable investment for most analysts.

What is Twist Bioscience's price target?

Twist Bioscience's price target, set by 13 Wall Street analysts, averages $67.83 over the next 12 months. The price target range spans from $52 at the low end to $85 at the high end, suggesting a potential -8.40% change from the previous closing price of $74.05.

How does Twist Bioscience stock forecast compare to its benchmarks?

Twist Bioscience's stock forecast shows a -8.40% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (19.09%).

What is the breakdown of analyst ratings for Twist Bioscience over the past three months?

  • June 2026: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 10.00% Strong Buy, 70.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 10.00% Strong Buy, 70.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Twist Bioscience’s EPS forecast?

Twist Bioscience's average annual EPS forecast for its fiscal year ending in September 2026 is $-1.66, marking a 27.69% increase from the reported $-1.3 in 2025. Estimates for the following years are $-1.08 in 2027, $-0.49 in 2028, and $0.04 in 2029.

What is Twist Bioscience’s revenue forecast?

Twist Bioscience's average annual revenue forecast for its fiscal year ending in September 2026 is $438.47M, reflecting a 16.44% increase from the reported $376.57M in 2025. The forecast for 2027 is $522.91M, followed by $605.5M for 2028, and $708.05M for 2029.

What is Twist Bioscience’s net income forecast?

Twist Bioscience's net income forecast for the fiscal year ending in September 2026 stands at $-96.838M, representing an 24.68% increase from the reported $-77.67M in 2025. Projections indicate $-80.934M in 2027, $-28.138M in 2028, and $2.32M in 2029.